Sith Sathornsumetee

Siriraj Hospital — Thailand

Medicine · Health Sciences

35h-index10.7kcitations132works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(77), Cancer, Hypoxia, and Metabolism(24), Brain Metastases and Treatment(22), MicroRNA in disease regulation(13), Histone Deacetylase Inhibitors Research(13)

Publications131 total

Resveratrol as a Novel <scp>YAP</scp> Inhibitor Targeting Glioblastoma Progression and Sensitizing to Chemotherapy
Cancer Science·2026Open Access
Recovery of glioblastoma cells derived from patients after a decade of cryopreservation for drug response studies
Scientific Reports·2025Open Access
Mesenchymal, non-meningothelial tumors involving the central nervous system
2025
Enhanced Anticancer Effects Through Combined Therapeutic Model of Macrophage Polarization and Cancer Cell Apoptosis by Multifunctional Lipid Nanocomposites
Journal of Biomedical Materials Research Part A·2025Open Access
Clinical improvements in temporospatial gait variables after a spinal tap test in individuals with idiopathic normal pressure hydrocephalus
Scientific Reports·2024· 7 citedOpen Access
GLIMMERS: glioma molecular markers exploration using long-read sequencing
Bioinformatics Advances·2024· 1 citedOpen Access
Exploiting nanopore sequencing for characterization and grading of <i>IDH</i>‐mutant gliomas
Brain Pathology·2023· 11 citedOpen Access
Supplementary Table S1 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Table S3 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Data from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Table S3 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Table S1 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Data from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
2023Open Access
Supplementary Figure 3 from Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
2023Open Access
Supplementary Figure 3 from Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
2023Open Access
Supplementary Figures 1-7 from Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
2023Open Access
Supplementary Figure 5 from Targeting Cancer Stem Cells through L1CAM Suppresses Glioma Growth
2023Open Access
Data from Stem Cell–like Glioma Cells Promote Tumor Angiogenesis through Vascular Endothelial Growth Factor
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Jeremy N. Rich(37), Henry S. Friedman(25), David A. Reardon(24), James J. Vredenburgh(22), Annick Desjardins(22), James E. Herndon(20), Roger E. McLendon(15), Jennifer A. Quinn(13), Sridharan Gururangan(13), Darell D. Bigner(12), Allan H. Friedman(12), John H. Sampson(8), Anita B. Hjelmeland(7), Jennifer Marcello(6), Jeannette M. Dowell(5), Katherine B. Peters(5), April Coan(5), Nattika Saengkrit(4), Shideng Bao(3), James M. Provenzale(3)